The vasoactive intestinal peptide (VIP) has emerged as one of the most discussed compounds in chronic inflammatory response syndrome (CIRS) research and mold illness treatment communities. This 28-amino-acid neuropeptide, naturally produced in the gut, pancreas, and central nervous system, functions as a potent anti-inflammatory and immunoregulatory agent with documented effects across multiple organ systems. Its role in CIRS protocols, particularly through nasal spray delivery, has driven substantial research interest from investigators studying biotoxin-related illness.

This guide consolidates the current vasoactive intestinal peptide research landscape as of 2026. It covers VIP’s mechanism of action as an anti-inflammatory neuropeptide, the clinical evidence from CIRS and autoimmune research, comparisons with other anti-inflammatory peptides including KPV and BPC-157, nasal spray delivery protocols, and safety considerations. Researchers investigating inflammatory conditions and immune dysregulation will find the primary references and comparative context needed to evaluate VIP’s place in their research programs.

The growing interest in VIP reflects a broader shift in peptide research toward immune modulation and chronic inflammatory conditions. As researchers move beyond acute injury healing into complex immune-mediated pathology, neuropeptides like VIP offer mechanisms that bridge the nervous and immune systems in ways that traditional anti-inflammatory compounds cannot.

What Is VIP? Structure, Origin, and Biology

Vasoactive intestinal peptide is a 28-amino-acid linear neuropeptide first isolated from porcine small intestine by Said and Mutt in 1970. Despite its name suggesting a gut-specific function, VIP is widely distributed throughout the body. It is produced by neurons in the central and peripheral nervous systems, immune cells, endothelial cells, and enteric neurons throughout the gastrointestinal tract.

VIP belongs to the glucagon-secretin superfamily of peptides, which includes PACAP (pituitary adenylate cyclase-activating polypeptide), secretin, and glucagon. Its amino acid sequence is highly conserved across species, suggesting critical biological functions that have been maintained through evolutionary selection pressure.

The peptide exerts its effects through two G-protein-coupled receptors: VPAC1 and VPAC2. VPAC1 is widely expressed in the lungs, intestine, liver, and immune cells. VPAC2 is found primarily in the central nervous system, pancreas, and smooth muscle. Both receptors couple to adenylyl cyclase, and receptor activation increases intracellular cyclic AMP (cAMP), which mediates the downstream anti-inflammatory and vasodilatory effects.

Under normal physiological conditions, VIP functions as a neurotransmitter and neuromodulator. It regulates circadian rhythm in the suprachiasmatic nucleus, modulates immune cell function, promotes vasodilation, stimulates water and electrolyte secretion in the intestine, and inhibits gastric acid production. This broad physiological role explains why VIP deficiency or dysregulation has been implicated in multiple disease states.

How Does Vasoactive Intestinal Peptide Work as an Anti-Inflammatory?

VIP’s anti-inflammatory mechanism is multifaceted, operating through direct suppression of pro-inflammatory mediators, promotion of regulatory immune cell populations, and modulation of the innate immune response. These mechanisms distinguish it from simple anti-inflammatory drugs and position it as an immunoregulatory agent.

NF-kB Pathway Suppression

VIP inhibits the nuclear factor kappa B (NF-kB) signaling pathway, one of the master regulators of inflammatory gene expression. By suppressing NF-kB activation in macrophages and dendritic cells, VIP reduces the production of pro-inflammatory cytokines including TNF-alpha, IL-6, IL-12, and IL-1beta. Published research in the Journal of Immunology documents these anti-inflammatory effects across multiple immune cell types. A comprehensive review in Nature Reviews Immunology further details VIP’s role as a key mediator bridging the neuroendocrine and immune systems.

Regulatory T Cell Induction

VIP promotes the differentiation and expansion of regulatory T cells (Tregs), which are essential for maintaining immune tolerance and preventing autoimmune reactions. This immunoregulatory effect shifts the immune balance from inflammatory Th1/Th17 responses toward tolerogenic Treg-mediated suppression. For CIRS researchers, this mechanism is particularly relevant because chronic biotoxin exposure is thought to disrupt immune regulation in ways that Treg promotion could help restore.

Dendritic Cell Modulation

VIP converts dendritic cells from an inflammatory to a tolerogenic phenotype. Tolerogenic dendritic cells present antigens in a context that promotes immune tolerance rather than immune activation. This dendritic cell reprogramming is a potent upstream mechanism for reducing chronic inflammation, as dendritic cells orchestrate the adaptive immune response.

Neuroprotective and Barrier Functions

Beyond immune modulation, VIP protects neuronal tissue and maintains barrier integrity in the gut and lungs. Published research demonstrates that VIP supports tight junction protein expression in intestinal epithelial cells, which is relevant to “leaky gut” models frequently discussed in CIRS and chronic inflammatory disease research. This barrier-protective function overlaps mechanistically with BPC-157’s gastrointestinal protective effects, though the two peptides work through distinct pathways.

VIP in CIRS and Mold Illness Research

The application of vasoactive intestinal peptide in chronic inflammatory response syndrome (CIRS) research is closely associated with the work of Dr. Ritchie Shoemaker, who identified VIP deficiency as a common finding in patients with biotoxin-related illness and incorporated VIP nasal spray into the later stages of his CIRS treatment protocol.

VIP Deficiency in CIRS

Published research from the Shoemaker protocol documents that many CIRS patients have measurably low serum VIP levels. This deficiency correlates with symptoms including chronic fatigue, cognitive dysfunction, respiratory difficulties, and dysregulated inflammatory markers. The observation that VIP levels are specifically depressed in biotoxin-exposed patients, while other neuropeptides may remain normal, supports the hypothesis that VIP pathway disruption is a specific feature of CIRS pathophysiology.

Nasal Spray Protocol

VIP is administered via nasal spray in the Shoemaker CIRS protocol, typically as the final step after other interventions have addressed cholestyramine binding, MARCoNS treatment, and MSH normalization. The nasal spray route provides direct access to the nasal mucosa and indirect CNS delivery through the olfactory pathway, bypassing the rapid enzymatic degradation that limits VIP’s bioavailability after systemic administration.

Published reports describe improvements in pulmonary function, inflammatory markers, and quality of life measures in CIRS patients treated with VIP nasal spray after completion of the preceding protocol steps. However, the evidence base consists primarily of case series and observational studies rather than large randomized controlled trials.

Regulatory Peptide Measurements

VIP is typically measured alongside other regulatory peptides and inflammatory markers in CIRS evaluation panels. The combination of low VIP, low MSH (melanocyte-stimulating hormone), elevated TGF-beta 1, and elevated C4a complement split product represents a characteristic biomarker pattern described in CIRS literature. Researchers investigating this biomarker constellation can find related content in the peptides for immune support guide.

VIP vs KPV vs BPC-157: How Do Anti-Inflammatory Peptides Compare?

Researchers investigating anti-inflammatory peptides have three well-characterized options with distinct but sometimes complementary mechanisms. The table below highlights the key differences.

These three compounds operate at different levels of the inflammatory cascade. VIP works upstream as an immunoregulatory neuropeptide that rebalances the overall immune response. KPV provides targeted NF-kB suppression that directly inhibits inflammatory cytokine production. BPC-157 works at the tissue level to promote repair and cytoprotection. For researchers designing multi-peptide anti-inflammatory protocols, these mechanistic differences suggest complementary rather than redundant effects.

Both KPV and BPC-157 are available from PSPeptides with independent COAs. For deeper coverage of these compounds, see the KPV anti-inflammatory guide, the KPV spray guide, and the peptides for gut health overview.

VIP Dosing Protocols in Published Research

Dosing protocols for vasoactive intestinal peptide vary significantly depending on the research context. The CIRS nasal spray protocol represents the most commonly referenced dosing regimen, but published research has evaluated VIP through multiple routes and dose ranges.

The CIRS nasal spray protocol is the most directly relevant for researchers following the Shoemaker framework. The intranasal route was selected specifically because VIP has a very short plasma half-life (approximately 1-2 minutes) due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other peptidases. Nasal delivery provides local mucosal effects and limited CNS access while avoiding the near-instant systemic degradation that renders IV VIP impractical for chronic dosing.

The short half-life is a fundamental pharmacological limitation that distinguishes VIP from more stable anti-inflammatory peptides. For comparison, KPV and BPC-157 have substantially longer effective half-lives, making them more practical for sustained anti-inflammatory research protocols. The peptides for immune support guide covers these more stable alternatives in detail.

VIP in Pulmonary and Autoimmune Research

Beyond CIRS, vasoactive intestinal peptide has been investigated in several other inflammatory and autoimmune conditions. The breadth of VIP’s immunoregulatory activity makes it relevant to any disease model involving chronic inflammation or immune dysregulation.

Pulmonary Arterial Hypertension

VIP deficiency has been documented in the lung tissue of patients with pulmonary arterial hypertension (PAH). Published research demonstrates that VIP acts as a pulmonary vasodilator and anti-proliferative agent in the pulmonary vasculature. Inhaled VIP has been evaluated in clinical case series with reports of improved hemodynamics and exercise capacity, though large randomized trials have not been completed.

Rheumatoid Arthritis Models

Preclinical studies have demonstrated that VIP reduces joint inflammation and bone destruction in collagen-induced arthritis models. The mechanism involves suppression of pro-inflammatory cytokines in the synovium and promotion of regulatory T cell populations in draining lymph nodes. These findings published in the Annals of the Rheumatic Diseases highlight VIP’s potential as an immunomodulatory agent in autoimmune joint disease.

Inflammatory Bowel Disease

VIP’s role in the enteric nervous system makes it a natural candidate for inflammatory bowel disease research. Published studies show that VIP reduces intestinal inflammation in experimental colitis models through suppression of mucosal immune activation and promotion of epithelial barrier integrity. This gastrointestinal application overlaps with the research profiles of both KPV and BPC-157, creating opportunities for comparative and combination studies.

Sepsis and Systemic Inflammation

Preclinical research has demonstrated that VIP administration reduces mortality and organ damage in sepsis models. The mechanism involves suppression of the systemic inflammatory cytokine storm that drives sepsis-related organ failure, combined with preservation of vascular integrity through endothelial barrier stabilization. These findings highlight VIP’s potential in critical care settings where immune dysregulation drives life-threatening pathology.

Stability and Practical Challenges of VIP Research

The practical challenges of working with vasoactive intestinal peptide stem primarily from its rapid enzymatic degradation. With a plasma half-life of only 1-2 minutes, VIP requires careful consideration of delivery route, formulation stability, and dosing frequency to achieve meaningful tissue exposure.

Researchers working with VIP in laboratory settings must account for degradation during sample preparation, storage, and administration. Protease inhibitors are commonly added to VIP solutions used in cell culture experiments to prevent premature degradation. For in vivo studies, the nasal spray formulation provides the best balance of practical convenience and effective delivery.

This stability challenge has driven interest in VIP analogs and alternative delivery systems, including nanoparticle encapsulation, PEGylation, and sustained-release depot formulations. These approaches aim to extend VIP’s effective half-life sufficiently for systemic anti-inflammatory applications while preserving its receptor binding activity. However, none of these modified formulations have reached widespread clinical use.

For researchers seeking anti-inflammatory peptides with inherently superior stability profiles, both KPV and BPC-157 offer substantially longer effective half-lives without requiring specialized delivery technologies. The KPV anti-inflammatory guide and BPC-157 research guide cover these more practical alternatives in detail.

What Is the Safety Profile of VIP?

As an endogenous neuropeptide, VIP has a generally favorable safety profile when used at physiological replacement doses. Published clinical reports from CIRS treatment describe the nasal spray formulation as well-tolerated by most patients.

The most commonly reported side effects include nasal congestion, rhinorrhea (runny nose), and transient facial flushing — effects consistent with VIP’s vasodilatory properties. At higher doses, vasodilation can produce hypotension, particularly in susceptible individuals. Gastrointestinal effects including watery diarrhea can occur at supraphysiological doses, reflecting VIP’s natural role in promoting intestinal water secretion.

A theoretical concern is VIP’s role as a growth factor for certain tumor types. Published research has documented VPAC receptor expression on various cancers, and VIP can promote tumor cell proliferation in vitro. While this does not establish clinical risk at replacement doses, it represents a consideration that researchers should be aware of, particularly for individuals with active malignancies.

The Shoemaker protocol specifies that VIP nasal spray should only be initiated after other CIRS treatment steps are completed and specific biomarker criteria are met, including negative MARCoNS culture and normalized lipase levels. This sequential approach is designed to minimize adverse effects by ensuring that the inflammatory environment has been partially addressed before VIP is introduced.

Where to Buy Research-Grade Anti-Inflammatory Peptides

PSPeptides carries the most established anti-inflammatory peptides used in gut health, immune modulation, and tissue repair research, including research-grade VIP peptide in a 10MG vial. Every compound ships with independent analytical verification.

Third-party Certificates of Analysis. Each batch of VIP, KPV and BPC-157 includes independent laboratory COAs verifying purity and identity through HPLC and mass spectrometry.

Same-day shipping from US warehouses. Orders placed before the daily cutoff ship the same business day. Fast domestic fulfillment protects peptide stability during transit.

Complete supply bundles. PSPeptides stocks bacteriostatic water, nasal spray kits, syringes, and all supporting supplies alongside peptide products. One order covers everything.

Flexible checkout with no barriers. All major credit cards accepted, plus Afterpay and Klarna installment options. No cryptocurrency requirements and no invasive KYC verification — just a standard e-commerce checkout.

Browse the full anti-inflammatory and gut health peptide selection at pspeptides.com/shop.

Frequently Asked Questions

What is VIP used for in CIRS treatment research?

Vasoactive intestinal peptide is used in the final stage of the Shoemaker CIRS protocol as a nasal spray to address VIP deficiency commonly observed in biotoxin-exposed patients. Published reports describe improvements in pulmonary function, inflammatory biomarkers, and quality of life measures. It is administered after preceding protocol steps including cholestyramine binding and MARCoNS eradication have been completed.

How is VIP delivered as a nasal spray?

VIP nasal spray delivers the peptide directly to the nasal mucosa, where it can access local immune tissue and reach the CNS indirectly through the olfactory pathway. This route bypasses the rapid enzymatic degradation that limits VIP’s effectiveness after oral or systemic administration. The nasal spray formulation requires compounding with appropriate stabilizers and preservatives to maintain peptide activity.

What is the difference between VIP and KPV for inflammation?

VIP is a 28-amino-acid neuropeptide that works through VPAC1/2 receptors to broadly regulate immune function, promoting regulatory T cells and converting dendritic cells to a tolerogenic phenotype. KPV is a three-amino-acid peptide derived from alpha-MSH that directly suppresses NF-kB signaling, the master inflammatory transcription factor. VIP operates at the immune system regulation level, while KPV provides more targeted inflammatory pathway suppression. The two mechanisms are complementary rather than redundant.

All PSPeptides products are sold exclusively for research and laboratory use.